Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy At this time, all the above hepatitis markers remained unmodified. After four weekly standard doses of rituximab a GPR was recorded, and then six monthly courses (150 mg/m 2 ) of the same agent were administered as maintenance therapy. In September 2004, being the patient in CR, he was admitted with acute hepatitis. HBV DNA strains (200 000 copies/ml) were detected, whereas the HbsAg-negative status persisted.
Under antiviral treatment with lamivudine, the viraemia decreased to 3300 copies/ml within 2 weeks. Nevertheless, hepatic function did not recover, and the patient died 32 days after his admission.
Although reactivation of HBV in HBsAg-positive patients is a well-documented complication of cytotoxic treatments, 4, 5 to the best of our knowledge, this is the first case of HBV reactivation in a B-CLL patient after rituximab. Moreover, we recorded the presence of HBcAb and HBeAb associated with the negativity of HbsAg and HBsAb, indicating that these findings are a longlasting occult infection of a HBV variant strain. Given the high efficacy of prophylaxis with lamivudine, testing HBV DNA before immunosuppressive and cytotoxic treatments, including the anti-CD20 antibodies, should be recommended in order to identify HBV carriers among patients presenting HBcAb alone without any other serological HBV markers, since HBsAg routine tests may be unreliable in S-gene mutated variants. Notch signaling plays a key role in the cell fate decision at various differentiation branch points. 1 In mammals, it has been well recognized that the deregulated activation of Notch signaling leads to tumor development. 2 This concept is highlighted by a recent report demonstrating that as much as 60% of childhood T-cell acute lymphoblastic leukemia (T-ALL) has mutations in the Notch1 gene. 3 The resulting amino-acid changes have been found in the heterodimerization (HD) domains at the C-and N-termini of the extracellular and transmembrane subunits (HD EC and HDt domains), respectively, and the transcriptional activation (TA) and PEST domains at the cytoplasmic region of the transmembrane subunit. The former mutations are thought to reduce the affinity between the two subunits, which subsequently leads to ligand-independent g-cleavage of the Notch1 transmembrane subunit and production of an activated Notch1 intracellular domain. In the latter, insertion or deletion mutations introduce a premature stop codon that results in truncation of the PEST domain, which 
